Hospital General de Castellón-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2023

  1. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

  2. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

2021

  1. Improved short-term outcomes of kidney transplants in controlled donation after the circulatory determination of death with the use of normothermic regional perfusion

    American Journal of Transplantation, Vol. 21, Núm. 11, pp. 3618-3628

  2. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. Changes and Clinical Consequences of Smoking Cessation in Patients With COPD: A Prospective Analysis From the CHAIN Cohort

    Chest, Vol. 154, Núm. 2, pp. 274-285

2017

  1. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD

    The European respiratory journal, Vol. 50, Núm. 5

2015

  1. Differential effect of modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD

    Chest, Vol. 148, Núm. 1, pp. 159-168

  2. Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 269-278

  3. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2014

  1. Clinical application of the COPD assessment test: Longitudinal data from the COPD history assessment in Spain (CHAIN) Cohort

    Chest, Vol. 146, Núm. 1, pp. 111-122

  2. Erratum: New GOLD classification: Longitudinal data on group assignment [Respir Res. 15, (2014) 3, 10.1186/1465-9921-15-3]

    Respiratory Research

  3. New GOLD classification: Longitudinal data on group assignment

    Respiratory Research, Vol. 15, Núm. 1

2011

  1. Fe de errores de «La guardia específica de neurología en la formación del médico residente en España»

    Neurologia

2010

  1. La guardia específica de Neurología en la formación del médico residente en España

    Neurologia, Vol. 25, Núm. 9, pp. 557-562

2009

  1. Prevalencia de enfermedad arterial periférica asintomática en pacientes con ictus isquémico no cardioembólico

    Neurologia, Vol. 24, Núm. 6, pp. 366-372

  2. The Spanish HIV BioBank: A model of cooperative HIV research

    Retrovirology, Vol. 6

2007

  1. Prevalencia de enfermedad arterial periférica estimada mediante el índice tobillo-brazo en pacientes con síndrome metabólico. Estudio MERITO I

    Revista Clinica Espanola, Vol. 207, Núm. 5, pp. 228-233